Management of patients with HBeAg-negative chronic hepatitis B

Postgraduate Medical Journal

Volumn 83, Issue 975, 2007, Pages 32-39

  Saikia, Nripen ^a   Talukdar, Rupjyoti ^a   Mazumder, Subhasish ^a   Khanna, Sudeep ^a   Tandon, Rakesh ^a  

^a Pushpawati Singhania Research Institute   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA INTERFERON A; CLEVUDINE; ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TELBIVUDINE; TENOFOVIR;

ADULT; CHILD; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; KIDNEY INJURY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER INJURY; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; FORECASTING; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS;

EID: 33847004354     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.044826     Document Type: Review

References (67)

1. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999;17:1730-3.
2. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18.
3. de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
4. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995;21:77-82.
5. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:135.
6. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-10.
7. Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated pre-core and core promoter variants. J Viral Hepat 2002;9:52-61.
8. Keefe E, Dieterich D, Steve-Huy B. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol, 2004;2:87-106.
9. Papatheodoridis GV, Manesis E, Hadziyannis SJ, et al. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13.
10. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24.
11. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-15.
12. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-9.
13. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B 2000. Summary of a workshop. Gastroenterology 2001;120:1828-53.
14. Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-7.
15. Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology, 1992 Apr, 15:584-9.
16. Hadziyannis S, Bramou T, Makris A, et al. Interferon alfa-2b treatment of HBeAg negative/serum HBVDNA positive chronic active hepatitis type B. J Hepatol, 1990;11(Suppl 1):S133-6.
17. Lampertico P, Del Ninno E, Manzin A, et al. A Randomized controlled trial of a 24 months course of interferon alfa 2b in patients with chronic hepatitis B who had Hepatitis B who had HBV DNA without hepatitis B e antigen in serum. Hepatology 1997;26:1621-5.
18. Pastore G, Santantonio T, Milella M, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992;14:221-5.
19. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-70.
20. Papatheodoridis GV, Petraki K, Cholongitas E, et al. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2005;12:199-206.
21. Papatheodiridis GV, Petraki K, Cholongital E, et al. Impact of interferon-α therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis. B J Viral Hepat 2005;12:119-206.
22. Manesis EK, Hadziyannis SJ. Interferon α treatment and retreatment of HBeAg-negative chronic hepatitis B. Gastroenterology 2001;121:101-9.
23. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a(40 kDa): an advance in the treatment of hepatitis B e antigen positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
24. Marcellin P, Lau GK, Bonino F, et al. Peginterferon α-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
25. Marcellin P, Lau GKK, Bonino F, et al. Sustained response to peginterferon α-2a (40 KD) (Pegasys) in HBeAg-negative chronic hepatitis B. 1-year follow-up data from a large, randomised multinational study [A512]. J Hepatol 2005;42(Suppl 2):185-6.
26. Lai CL, Chien RN, Leung NW, et al. One-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
27. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
28. Gaun R, Lai CL, Liaw YF, et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with CHB. J Gastroenterol Hepatol 2001;16(Suppl):A60-1.
29. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-96.
30. Huang YH, Wu JC, Chang T-T, et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for HBeAg-negative CHB in Taiwan. J Viral Hepat, 2003;10:277-84.
31. Santantonio T, Mazzola M, Iacovozzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6.
32. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
33. Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000;61:398-400.
34. Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis B [abstract]. J Hepatol 1999;30(Suppl 1):117.
35. Papatheoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-26.
36. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004;99:57-63.
37. Nikolaidis N, Vassiliadis T, Giouleme O, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant 2005;19:321-6.
38. Yoshida EM, Ramji A, Chatur N, et al. Regression of cirrhosis associated with hepatitis B e antigen-negative chronic hepatitis B infection with prolonged lamivudine therapy. Eur J Gastroenterol Hepatol, 2004;16;355-8..
39. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
40. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B. N Engl J Med 2003:800-7.
41. Knight W, Hayashi S, Benhamou Y, et al. Dosing guidelines for adefovir dipivoxil in the treatment of HBV infected patients with renal or hepatic impairment. J Hepatol 2002;36(Suppl 1):136.
42. Heathcote E, Jeffers L, Perrillo R, et al. Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil therapy in chronic HBV infection. J Hepatol 2002;36(Suppl 1):110.
43. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil for presumed precore mutant chronic hepatitis B. J Hepatol 2003;38(Suppl 2):143.
44. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352: 2673-81.
45. Hadziyannis S, Tassopoulos NC, Chang TT, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy [abstract]. Hepatology 2005;42:754A.
46. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5.
47. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-3.
48. De Man R, Wolters L, Nevens F, et al. A study of oral entecavir given for 28 days in both treatment-naive and pre-treated subjects with chronic hepatitis [abstract]. Hepatology 2000;32:376A.
49. Tassopoulos N, Hadziyannis S, Cianciara J, et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy [abstract]. Hepatology 2001;34:340A.
50. Chang TT, Gish RG, de Man R, et al. A Comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
51. Chang TT, Gish RG, Hadziyannis SJ, et al. BEHoLD Study Group. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209.
52. Cheinquer H, shouval D, Lai CL, et al. Entecavir demonstrate superior histological and virologic efficacy over lamivudine in nucleoside-naive HbeAg-ve chronic hepatitis B. Results of Phase III trial ETV-027. Hepatology 2004;40:728A.
53. Colonno R, Rose R, Levine S, et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients [abstract]. Hepatology 2005;42:573A.
54. Ogui K, Ali T, Mustafa T, et al. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. J Microbiol Immunol Infect 2005;38:262-6.
55. Karabay O, Tamer A, Tahtaci M, et al. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. J Microbiol Immunol Infect 2005;38:262-6.
56. Economou M, Manolakopoulos S, Trikalinos TA, et al. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005;11:5882-7.
57. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2006;23:99-106.
58. Yoo BC, Kim JH, Lee KS, et al. A 24-week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalization of aminotransferase levels for 24 weeks off-treatment in HBeAg(+) chronic hepatitis B patients [abstract]. Hepatology 2005;42:270A.
59. Yoo BC, Chung YH, Han BH, et al. Clevudine is highly efficacious in HBeAg chronic hepatitis B patients with a sustained antiviral effect after cessation of therapy [abstract]. Hepatology 2005;42:268A.
60. Lai CL, Gane E, Liaw YF, et al. Telbivudine vs lamivudine for chronic hepatitis B: first-year results from the International Phase III GLOBE Trial [abstract]. Hepatology 2005;42:748A.
61. van Bommel F, Mauss S, Zollner B, et al. Long-term effect of tenofovir in the treatment of lamivudine-resistant hepatitis B virus infections in comparison to adefovir [abstract]. Hepatology 2005;42:269A.
62. Mauss S, Nelson M, Lutz T, et al. First line combination therapy of chronic hepatitis B with tenofovir plus lamivudine versus sequential therapy with tenofovir monotherapy after lamivudine failure [abstract]. Hepatology 2005;42:574A.
63. Lok AS, McMohan BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations, Hepatology 2004;39:857-61.
64. De Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on hepatitis B. J Hepatol 2003;39(Suppl 1):S3-25.
65. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003;18:239-45.
66. Wang C, Deubner H, Shuhart M, et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection [abstract]. Hepatology 2005;42:573A.
67. Nguyen M, Trinh H, Garcia RT, et al. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation [abstract]. Hepatology 2005;42:593A.